The new version of the North American Free Trade Agreement between the U.S., Canada, and Mexico is prompting concerns among generic drug makers and consumer advocates who argue language that is designed to bolster intellectual property rights for medicines will hurt taxpayers and patients.

At issue is a provision that would grant 10 years of marketing exclusivity for biologics, which are pricey medicines used to combat a wide variety of diseases, including many cancers. The language means that a company that wants to sell a lower-cost version of a brand-name biologic, which is known as a biosimilar, would be prevented from doing so for a decade.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy